<DOC>
	<DOCNO>NCT00698126</DOCNO>
	<brief_summary>This trial conduct Europe . The aim observational study evaluate incidence major hypoglycaemic episode patient type 2 diabetes treat NovoRapid® Soluble Human Insulin normal clinical practice condition .</brief_summary>
	<brief_title>Observational Study Patients Using NovoRapid® Soluble Human Insulin Treatment Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Patients type 2 diabetes Treatment Insulin Aspart ( NovoRapid® ) Soluble Human Insulin minimum 3 month maximum 3 year Patients endstage renal failure Patients serious liver disease Patients concomitant malignant disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>